Table 1.
Patients | ||
---|---|---|
n = 87 | ||
Male sex, n (%) | 64 | ( 74 ) |
Follow-up years* | 7.3 | (4.5 - 8.9) |
Age at diagnosis* | 44 | (33 - 52) |
Symptomatic at diagnosis, n (%) | 37 | ( 43 ) |
Inflammatory bowel disease, n (%) | 66 | ( 76 ) |
Biopsy at diagnosis, n (%) | 65 | ( 75 ) |
Biopsy stage* | 2 | (1 - 3) |
Laboratory values at diagnosis: | ||
Alkaline phosphatase (ULN ratio)* | 2.8 | (1.8 - 4.6) |
AST (U/L)* | 74 | (44.5 - 125) |
Total bilirubin (mg/dL)* | 1.1 | (0.7 - 1.8) |
INR* | 1 | (0.9 - 1) |
Albumin (g/dL)* | 4 | (3.7 - 4.3) |
Initial MELD score* | 8 | (7 - 10.5) |
Initial Mayo risk score* | 0.12 | (0 - 0.84) |
AST, aspartate aminotransferase; INR, international normalized ratio; MELD, model for end-stage liver disease; ULN, upper limit of normal.
Median with inter-quartile range included parenthetically.